Get the Stockscreener App
5.40
3.23%
-0.18
Savara Inc stock is traded at $5.40, with a volume of 1.19M.
It is down -3.23% in the last 24 hours and down -11.62% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$5.58
Open:
$5.53
24h Volume:
1.19M
Relative Volume:
0.49
Market Cap:
$1.10B
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-16.36
EPS:
-0.33
Net Cash Flow:
$-51.36M
1W Performance:
-10.30%
1M Performance:
-11.62%
6M Performance:
+110.94%
1Y Performance:
+92.86%
1-Day Range:
$5.35
$5.64
1-Week Range:
$5.35
$6.005
52-Week Range:
$1.89
$7.005
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.40 | 1.14B | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI - BioSpace
Savara secures additional $75m in debt financing for potential drug launch - Investing.com Australia
Hercules Capital Ties Savara Funding To FDA Milestone And Valuation Case - simplywall.st
A Look At Hercules Capital (HTGC) Valuation After The Expanded Savara Loan Agreement - Yahoo Finance
Savara Reports Amendment to Hercules Capital Debt Facility - marketscreener.com
Savara Grants Equity Awards to New Hires as It Advances Rare Lung Drug - MyChesCo
How Investors May Respond To Savara (SVRA) Adding Approval-Linked Hercules Credit To Its Liquidity Toolkit - simplywall.st
Savara Ekes up on Deal with Hercules - Baystreet.ca
Savara Enters New Material Definitive Agreement and Obligation - TipRanks
Savara amends loan agreement to access up to $105 million in term loans - Investing.com
Savara (SVRA) Faces Class Action Lawsuit Over Shareholder Losses - Intellectia AI
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
CEO Moves: Does Star Equity Holdings Inc have a competitive edgeLong Setup & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Rare lung drug nears FDA decision as PANTHERx, Savara seal US deal - MSN
Rare Lung Drug Nears FDA Decision as PANTHERx, Savara Seal U.S. Deal - mychesco.com
Savara Secures $75 Million Royalty Deal to Back Potential MOLBREEVI Launch - MSN
FDA clock restarts: Savara refiles MOLBREEVI for rare lung disease - MSN
Day Trade: What is the dividend yield of LIVEJuly 2025 Breakouts & Risk Managed Investment Strategies - baoquankhu1.vn
Aug Opening: Should I trade or invest in Savara Inc2025 Institutional Moves & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Savara Announces New Employment Inducement Grant - Business Wire
What Savara (SVRA)'s Exclusive PANTHERx MOLBREEVI Distribution Deal Means For Shareholders - simplywall.st
Aug Opening: Will Savara Inc benefit from government policyRate Cut & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress - MSN
Value Recap: Can Savara Inc disrupt its industryJobs Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
Savara Highlights Autoimmune PAP Burden in Updated Presentation - TipRanks
Lobbying Update: $30,000 of SAVARA INC. lobbying was just disclosed | SVRA Stock News - Quiver Quantitative
With 37% stake, Savara Inc. (NASDAQ:SVRA) seems to have captured institutional investors' interest - Yahoo Finance
Savara Inc. (NASDAQ:SVRA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Savara Inc. Announces Equity Awards for New Employees - MSN
Savara Inc. Grants Inducement Awards to New Employees with Stock Options & RSUs - MSN
How big funds are accumulating Savara Inc. (YB4P) stock2025 Price Action Summary & Capital Protection Trade Alerts - Улправда
Why Savara Inc. stock is favored by top institutions2025 Stock Rankings & Growth Focused Entry Reports - ulpravda.ru
How Savara Inc. stock compares to growth peers2025 Institutional Moves & AI Optimized Trading Strategy Guides - Улправда
The Bull Case For Savara (SVRA) Could Change Following Exclusive MOLBREEVI Distribution Deal With PANTHERx - simplywall.st
Market Fear: Will Savara Inc. stock outperform growth indexesMarket Risk Analysis & Smart Swing Trading Alerts - Улправда
How Savara Inc. stock benefits from global expansionJuly 2025 Movers & Fast Gaining Stock Strategy Reports - Улправда
Will Savara Inc. stock outperform growth indexes2025 Market WrapUp & AI Powered Market Trend Analysis - ulpravda.ru
Will Savara Inc. stock outperform tech sector in 20252025 Price Momentum & Daily Price Action Insights - Улправда
How Savara Inc. (YB4P) stock compares with top peersProduct Launch & Technical Confirmation Alerts - Улправда
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI - PharmiWeb.com
Savara : Corporate Presentation - MarketScreener
Can Savara Inc. stock beat market expectations this quarterJuly 2025 Review & Fast Gain Stock Trading Tips - ulpravda.ru
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* - Yahoo Finance Australia
Will Savara Inc. stock sustain high P E ratiosPortfolio Performance Summary & AI Forecasted Stock Moves - ulpravda.ru
Will Savara Inc. (YB4P) stock rise with strong economyBuy Signal & Fast Exit Strategy with Risk Control - Улправда
Will Savara Inc. stock reach all time highs in 20252025 Market Sentiment & Safe Investment Capital Preservation Plans - ulpravda.ru
Aug Volume: How Savara Inc stock compares to growth peersRisk Management & Growth Focused Investment Plans - moha.gov.vn
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):